Post by HCPLive

Article of the Week: Positive topline results from the phase 3 VALIANT study announced earlier this week provide insight into the benefit of systemic pegcetacoplan in patients with C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis. Learn more: